<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02798406</url>
  </required_header>
  <id_info>
    <org_study_id>2401BT-002P</org_study_id>
    <nct_id>NCT02798406</nct_id>
  </id_info>
  <brief_title>Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects</brief_title>
  <acronym>CAPTIVE</acronym>
  <official_title>A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>DNAtrix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>DNAtrix, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Glioblastoma (GBM) and gliosarcoma (GS) are the most common and aggressive forms of malignant&#xD;
      brain tumor in adults and can be resistant to conventional therapies. The purpose of this&#xD;
      Phase II study is to evaluate how well a recurrent glioblastoma or gliosarcoma tumor responds&#xD;
      to one injection of DNX-2401, a genetically modified oncolytic adenovirus, when delivered&#xD;
      directly into the tumor followed by the administration of intravenous pembrolizumab (an&#xD;
      immune checkpoint inhibitor) given every 3 weeks for up to 2 years or until disease&#xD;
      progression.&#xD;
&#xD;
      Funding Source-FDA OOPD&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In the initial phase of the study, up to 12 evaluable subjects will be enrolled in 3 dose&#xD;
      cohorts to determine the best dose of DNX-2401, as follows:&#xD;
&#xD;
        -  Cohort 1: Single dose DNX-2401 (5e8 vp) delivered intratumorally by cannula, followed by&#xD;
           intravenous pembrolizumab every 3 weeks (Q3W)&#xD;
&#xD;
        -  Cohort 2: Single dose DNX-2401(5e9 vp) delivered intratumorally by cannula, followed by&#xD;
           intravenous pembrolizumab every 3 weeks (Q3W)&#xD;
&#xD;
        -  Cohort 3: Single dose DNX-2401 (5e10 vp) delivered intratumorally by cannula, followed&#xD;
           by intravenous pembrolizumab every 3 weeks (Q3W)&#xD;
&#xD;
      Following the initial phase, up to 36 additional subjects diagnosed with recurrent&#xD;
      glioblastoma or gliosarcoma will be enrolled to receive a single of DNX-2401 determined in&#xD;
      the initial phase administered intratumorally followed by intravenous pembrolizumab every 3&#xD;
      weeks.&#xD;
&#xD;
      All subjects will return to the clinic for study follow-up visits at regular intervals for&#xD;
      safety monitoring, MRI scans and other assessments, for up to 2 years or until disease&#xD;
      progression. All subjects will be followed closely for safety and survival.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 2016</start_date>
  <completion_date type="Actual">June 30, 2021</completion_date>
  <primary_completion_date type="Actual">March 17, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective response rate (ORR)</measure>
    <time_frame>3.5 years</time_frame>
    <description>Interval tumor size reduction as measured from periodic MRI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3.5 years</time_frame>
    <description>Months alive following treatment as measured during periodic study visits</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to tumor response</measure>
    <time_frame>3.5 years</time_frame>
    <description>Months to response following treatment as measured during periodic MRIs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>3.5 years</time_frame>
    <description>Months of sustained response as measured during periodic study visits</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Brain Cancer</condition>
  <condition>Brain Neoplasm</condition>
  <condition>Glioma</condition>
  <condition>Glioblastoma</condition>
  <condition>Gliosarcoma</condition>
  <condition>Malignant Brain Tumor</condition>
  <condition>Neoplasm, Neuroepithelial</condition>
  <condition>Neuroectodermal Tumors</condition>
  <condition>Neoplasm by Histologic Type</condition>
  <condition>Neoplasm, Nerve Tissue</condition>
  <condition>Nervous System Diseases</condition>
  <arm_group>
    <arm_group_label>DNX-2401 + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intratumoral dose (1.0 mL) of DNX-2401 followed 7-9 days later by intravenous pembrolizumab, 200 mg, given every three weeks through 105 weeks (2 yrs.) or until progressive disease or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>DNX-2401</intervention_name>
    <description>On Day 0, following brain tumor biopsy and confirmation of recurrent tumor, a single injection of DNX-2401 is administered directly into the brain tumor.</description>
    <arm_group_label>DNX-2401 + pembrolizumab</arm_group_label>
    <other_name>Oncolytic virus</other_name>
    <other_name>Genetically-modified adenovirus</other_name>
    <other_name>Delta-24</other_name>
    <other_name>Delta-24-RGD</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>Sequential intravenous administration every three weeks beginning 7-9 days after Day 0/DNX-2401</description>
    <arm_group_label>DNX-2401 + pembrolizumab</arm_group_label>
    <other_name>KEYTRUDA</other_name>
    <other_name>lambrolizumab</other_name>
    <other_name>MK-3475</other_name>
    <other_name>SCH 900475</other_name>
    <other_name>Checkpoint inhibitor</other_name>
    <other_name>monoclonal antibody</other_name>
    <other_name>anti-PD1/PD-L1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  A single glioblastoma or gliosarcoma tumor with histopathological confirmation for&#xD;
             first or presenting second recurrence of glioblastoma or gliosarcoma at the time of&#xD;
             consent&#xD;
&#xD;
          -  Gross total or partial tumor resection is not possible or not planned&#xD;
&#xD;
          -  A single measurable tumor that is at least 10.0 mm longest diameter (LDi) X 10.0 mm&#xD;
             shortest diameter (SDi) and this tumor does not exceed 40.0 mm in LDi or SDi on&#xD;
             Screening MRI&#xD;
&#xD;
          -  Tumor recurrence or progression documented after previously failing surgical&#xD;
             resection, chemotherapy or radiation&#xD;
&#xD;
          -  Karnofsky performance status ≥ 70 %&#xD;
&#xD;
          -  Prior anti-tumor therapies must have been completed within time periods specified in&#xD;
             the protocol prior to DNX-2401 injection and toxic side effects must be mild, if&#xD;
             present&#xD;
&#xD;
          -  Demonstrate adequate organ function via specified laboratory test results&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Multiple (≥ 2) separate enhancing tumors&#xD;
&#xD;
          -  Tumor location on both sides of the brain and/or involvement that would present the&#xD;
             risk of injecting DNX-2401 into the ventricles of the brain&#xD;
&#xD;
          -  Tumor location in the brain stem&#xD;
&#xD;
          -  Requires or, based upon history, may require treatment with high-dose systemic&#xD;
             corticosteroids within 2 weeks of the start of intravenous pembrolizumab infusions and&#xD;
             within 2 weeks following the first infusion of pembrolizumab&#xD;
&#xD;
          -  Uncontrolled blood-sugar levels defined as HbA1c &gt; 7%&#xD;
&#xD;
          -  Previous treatment with any checkpoint inhibitor such as anti-PD1 or PD-L1 agents&#xD;
             including pembrolizumab (KEYTRUDA) or any other checkpoint inhibitor(s) (e.g.,&#xD;
             ipilimumab, nivolumab, etc.)&#xD;
&#xD;
          -  History of (non-infectious) or current active pneumonitis that required steroids&#xD;
             and/or a history of interstitial lung disease&#xD;
&#xD;
          -  Prior gene transfer therapy or prior therapy with a cytolytic virus of any type&#xD;
&#xD;
          -  Brain tumor that is not measurable on MRI or persons who are unable to have MRIs&#xD;
&#xD;
          -  Pregnant or nursing females&#xD;
&#xD;
        Note: Other protocol-defined inclusion and exclusion criteria may apply as outlined in the&#xD;
        relevant protocol version&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nancy Gady, BS</last_name>
    <role>Study Director</role>
    <affiliation>DNAtrix, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Arkansas for Medical Sciences (UAMS)</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UCLA Medical Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Minnesota Neurosurgery</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rutgers Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill-Cornell Medicine New York-Presbyterian</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UNC Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University James Cancer Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Austin-Midtown</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>June 9, 2016</study_first_submitted>
  <study_first_submitted_qc>June 13, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2016</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>brain</keyword>
  <keyword>Central Nervous System (CNS) diseases</keyword>
  <keyword>Central Nervous System (CNS) neoplasms</keyword>
  <keyword>CNS</keyword>
  <keyword>conditionally replicative adenovirus</keyword>
  <keyword>DNX-2401</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>KEYTRUDA</keyword>
  <keyword>MK-3475</keyword>
  <keyword>SCH 900475</keyword>
  <keyword>lambrolizumab</keyword>
  <keyword>neoplasm, germ cell and embryonal</keyword>
  <keyword>neoplasm, granular and epithelial</keyword>
  <keyword>Alcyone</keyword>
  <keyword>Alcyone Lifesciences</keyword>
  <keyword>AMC</keyword>
  <keyword>cannula</keyword>
  <keyword>MEMS cannula</keyword>
  <keyword>DNX-2401 + pembrolizumab</keyword>
  <keyword>Delta-24</keyword>
  <keyword>Delta-24-RGD</keyword>
  <keyword>Checkpoint inhibitor</keyword>
  <keyword>anti-PD1/PD-L1</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>monoclonal antibody</keyword>
  <keyword>KEYNOTE-192</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoviridae Infections</mesh_term>
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Glioblastoma</mesh_term>
    <mesh_term>Brain Neoplasms</mesh_term>
    <mesh_term>Gliosarcoma</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
    <mesh_term>Neoplasms by Histologic Type</mesh_term>
    <mesh_term>Neoplasms, Nerve Tissue</mesh_term>
    <mesh_term>Neoplasms, Neuroepithelial</mesh_term>
    <mesh_term>Nervous System Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Plan to share aggregate data at completion of study</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

